Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BHV 1310

Next Previous
Drug Profile

BHV 1310

Alternative Names: BHV-1310

Latest Information Update: 19 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biohaven Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunoglobulin G degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Myasthenia gravis

Most Recent Events

  • 16 Dec 2024 IND application approved for BHV 1310 in Myasthenia gravis
  • 16 Dec 2024 Biohaven plans a phase I trial for Myasthenia gravis in first quarter of 2025
  • 08 Feb 2024 BHV 1310 is available for licensing as of 08 Feb 2024. https://www.biohaven.com/about/global-collaboration/ (Biohaven website, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top